The Government’s medicines watchdog has called on pharmacists to rectify a problem with the patient information leaflet (PIL) in some packs of Zoledronic acid 5mg solution for infusion.
Related Article: Nearly twice as many patients in deprived areas prescribed dependency-forming meds
Some packs of the drug – used to treat bone diseases like osteoporosis – manufactured by Ranbaxy UK mistakenly contain the PIL for Temozolomide 180mg capsules instead of the correct one, the Medicines and Healthcare products Regulatory Agency (MHRA) warned today (4 April).
Pharmacists should check packs of the affected batch contains the right PIL and replace it with the correct one if they find packs that do not, the MHRA said. The correct PIL can be downloaded here.
Related Article: Finding sustainable funding solution is ‘matter of urgency’ for government
The affected batch is:
| Batch Number | Expiry Date | Pack Size | First Distributed |
| JKT1576A | 30/04/2020 | 1 x 100ml | 12th October 2018 |
Related Article: NICE recommends ‘game changer’ wearable tech for type 1 diabetes
Those with any enquiries should contact the Ranbaxy/Sun Pharmaceuticals customer services team on 020 8848 5050 or email [email protected]
Have your say
Please add your comment in the box below. You can include links, but HTML is not permitted. Please note that comments are not moderated before publication and the views expressed are those of the user and do not reflect the views of The Pharmacist. Remember that submission of comments is governed by our Terms and Conditions. You can also read our full guidelines on article comments here – but please be aware that you are legally liable for any libellous or offensive comments that you make. If you have a complaint about a comment or are concerned that a comment breaches our terms and conditions, please use the ‘Report this comment’ function to alert our web team.